SERUM VISFATIN RELATIONSHIP WITH GLYCEMIC CONTROL AND ADIPOSITY INDICES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Main Article Content

Syed Shahid Habib
Shahid Bashir
Syed Hamid Habib

Abstract

OBJECTIVE: To assess and compare serum visfatin levels with body composition adiposity indices and glycemic control in patients with Type 2 Diabetes Mellitus (T2DM).


METHODS: This observational case-control study was conducted at the Department of Physiology, College of Medicine and King Khalid University Hospital (KKUH), Riyadh, Saudi Arabia from April 2018 to March 2019. We studied sixty three individuals (33 T2DM and 30 controls) who were recruited from diabetes care clinics. Anthropometric, demographic and clinical characteristics were recorded from all participants and they were matched for age and gender. Venous blood samples were collected to measure visfatin and glycosylated hemoglobin (HbA1c). Adiposity indices were analyzed by Bio Impedance Analyzer (BIA).


RESULTS: Serum visfatin levels were 7.01±3.79 ng/ml in subjects with T2DM and 4.02±2.74 ng/ml in healthy subjects (p=0.046). Body composition indices including BMI, BMR, body fat percentage [BF%], body fat mass [BFM], truncal fat [TF], truncal fat mass [TFM] and visceral fat [VF] differences were not statistically significant between two groups. Serum visfatin levels were 9.29±3.44 ng/ml in T2DM with poor glycemic control (HbA1c >7.5%) as compared to 4.24±1.87 ng/ml in diabetic patients with good glycemic control (HbA1c <7.5%)  [p=0.001]. Visfatin positively correlated with BMI (r=0.284, p<0.05), BF% (r=0.302, p<0.05), BFM (r=0.280, p<0.05), VF (r=0.263, p<0.05) and HbA1c (r=0.394, p<0.01).


CONCLUSION: The results of this study show that T2DM patients have high serum visfatin levels. Moreover, higher levels of visfatin are observed with poor glycemic control and increasing body adiposity indices.

Article Details

How to Cite
Habib, S., S. Bashir, and S. Habib. “SERUM VISFATIN RELATIONSHIP WITH GLYCEMIC CONTROL AND ADIPOSITY INDICES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS”. KHYBER MEDICAL UNIVERSITY JOURNAL, Vol. 12, no. 4, Dec. 2020, pp. 263-7, doi:10.35845/kmuj.2020.20254.
Section
Original Articles

References

1. Chen MP, Chung FM, Chang DM, Tsai JCR, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91(1):295-9. DOI: 10.1210/jc.2005-1475.
2. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008;15(18):1851–62. DOI: 10.2174/092986708785133004.
3. Garten A, Petzold S, Schuster S, Körner A, Kratzsch J, Kiess W. Nampt and its potential role in inflammation and type 2 diabetes. Handb Exp Pharmacol 2011;(203):147–64. DOI: 10.1007/978-3-642-17214-4_7.
4. Zhao B, Zhang M, Han X, Zhang XY, Xing Q, Dong X, et al. Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism. PloS One 2013;8(12):e85403. DOI: 10.1371/journal.pone.0085403.
5. Brunetti, L, Recinella, L, Di Nisio, C, Chiavaroli A, Leone S, Orlando G, et al. Effects of visfatin/PBEF/NAMPT on feeding behaviour and hypothalamic neuromodulators in the rat. J Biol Regul Homeost Agents 2012;26(20):295-302.
6. Park BS, Jin SH, Park JJ, Park JW, Namgoong IS, Kim YI, et al. Visfatin induces sickness responses in the brain. PLoS One 2011;6(1):e15981. DOI: 10.1371/journal.pone.0015981.
7. Liang W, Ye DD. The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus. Cytokine Growth Factor Rev 2019;48:32-39. DOI: 10.1016/j.cytogfr.2019.06.002.
8. Hetta HF, Ez-Eldeen ME, Mohamed GA, Gaber MA, ElBadre HM, Ahmed EA, et al. Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance. Egypt J Immunol 2018;25(2):141-51.
9. Bawah AT, Seini MM, Abaka-Yawason A, Alidu H, Nanga S. Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus. Lipids Health Dis 2019 Dec 13;18(1):221. DOI: 10.1186/s12944-019-1169-2.
10. American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care 2010;33(Suppl 1):S11–S61. DOI: 10.2337/dc10-S011.
11. Habib SS. Serum resistin levels in patients with type 2 diabetes mellitus and its relationship with body composition. Saudi Med J 2012 May;33(5):495-9.
12. Duman H, Özyıldız AG, Bahçeci İ, Duman H, Uslu A, Ergül E. Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris. Ther Adv Cardiovasc Dis 2019 Jan-Dec;13:1753944719880448. DOI: 10.1177/1753944719880448.
13. Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, et al. Visfatin Induces Inflammation and Insulin Resistance via the NF-κB and STAT3 Signaling Pathways in Hepatocytes. J Diabetes Res 2019 Jul 17;2019:4021623. DOI: 10.1155/2019/4021623.
14. Mageswari R, Sridhar MG, Nandeesha H, Parameshwaran S, Vinod KV. Irisin and Visfatin Predicts Severity of Diabetic Nephropathy. Indian J Clin Biochem 2019 Jul;34(3):342-6. DOI: 10.1007/s12291-018-0749-7.
15. Guo A, Li K, Xiao Q. Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets? Exp Gerontol 2020 Oct 1;139:111022. DOI: 10.1016/j.exger.2020.111022.
16. Zhang M, Chen P, Chen S, Sun Q, Zeng QC, Chen JY, et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci 2014 Jun;18(11):1567-72.
17. Ebert T, Focke D, Petroff D, Wurst U, Richter J, Bachmann A, et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol 2014 Mar 8;170(4):501-6. DOI: 10.1530/EJE-13-1053.
18. Zheng LY, Xu X, Wan RH, Xia S, Lu J, Huang Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol Metab Syndr 2019 Jul 24;11:60. DOI: 10.1186/s13098-019-0455-5.
19. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Erdem G, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007 Apr 1;76(1):24–9. DOI: 10.1016/j.diabres.2006.07.031.
20. Quan XZ, Dong W, Gao K, Su W, Zhang LF. The Effect of Visfatin on Blood Glucose and Locomotor Activity in the Visfatin Transgenic Mouse. Chin J Comp Med 2009;(09):11–5.
21. Zhang YW, Zhang JQ, Liu C, Wei P, Zhang X, Yuan QY, et al. Memory dysfunction in type 2 diabetes mellitus correlates with reduced hippocampal CA1 and subiculum volumes. Chin Med J (Engl) 2015;128(4):465-71. DOI: 10.4103/0366-6999.151082